SEC FORM 4 8/3/2020

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Bancel Stephane				2. Issuer Name and Ticker or Trading Symbol Moderna, Inc. [MRNA]												/ner		
(Last) (First) (Middle) C/O MODERNA, INC. 200 TECHNOLOGY SQUARE					3. Date of Earliest Transaction (Month/Day/Year) 07/29/2020									X Officer (give title Other (specify below) Chief Executive Officer				
(Street) CAMBRIDGE	MA		139	4.	If Amenda	ment, Date	e of Origin	ginal Filed (Month/Day/Year)					6. Individ	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip	Table I - No	n-Deri	ivative	Securit	ios Acc	uired	Dien	nsad of	or B	anoficial	ly Owned					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date,	3. Transaction		4. Securities Acquired (A) or Disp			Disposed Of			. Ownership form: Direct (D) or ndirect (I) (Instr.	7. Nature of Indirect Beneficial			
						Code	v	Amount		(A) or (D)	Price	Reported Transaction(s) and 4)	J 4		Ownership (Instr. 4)			
Common Stock				07/29	9/2020			S ⁽¹⁾		9,00	00	D	\$82	6,684,8	58	D		
Common Stock				07/29	9/2020			G ⁽²⁾	V	1,000 D		(3)	6,683,858		D			
Common Stock			07/30	0/2020			S ⁽⁴⁾		10,000 D		\$77.98	7,824,880		I	See Footnote ⁽⁵⁾			
Common Stock													486,040		I	See Footnote ⁽⁶⁾		
Common Stock													9,160,9	78	I	See Footnote ⁽⁷⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		onversion Date Execution Da if Exercise (Month/Day/Year) if any (Month/Day/Year) erivative		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable an Expiration Date (Month/Day/Year)		В	nd 7. Title and Amount of Underlying Derivative (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V (A) (D)		(D)			Expiration Date	ration Nu		Amount or Number of Shares		Transactio (Instr. 4)	on(s)			

Explanation of Responses:

- 1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.
- 2. The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020.
- 3. The reported disposition represents a bona fide charitable gift made by the reporting person
- 4. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020.
- 4. This sale was ricetee pursuant to a Rule 1005-1 trading pian adopted on December 18, 2018, as amended on May 21, 2020.

 5. These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

 6. These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
- 7. These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

/s/ Lori Henderson, as Attorney-in-

Fact

** Signature of Reporting Person

Date

07/31/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.